Stock On Watch: Is Buying All-time Stock Like LeMaitre Vascular Inc a Winning Strategy?

Stock On Watch: Is Buying All time Stock Like LeMaitre Vascular Inc a Winning Strategy?

The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) reached all time high today, Nov, 10 and still has $38.97 target or 69.00% above today’s $23.06 share price. This indicates more upside for the $461.22 million company. This technical setup was reported by If the $38.97 PT is reached, the company will be worth $318.24 million more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 102,186 shares traded hands. LeMaitre Vascular Inc (NASDAQ:LMAT) has risen 51.36% since April 8, 2016 and is uptrending. It has outperformed by 45.71% the S&P500.

LeMaitre Vascular Inc (NASDAQ:LMAT) Ratings Coverage

Out of 9 analysts covering LeMaitre Vascular (NASDAQ:LMAT), 8 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 89% are positive. LeMaitre Vascular has been the topic of 22 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Mkt Perform” rating given on Thursday, September 10 by Barrington Research. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Buy” rating by TH Capital on Wednesday, July 29. The firm earned “Buy” rating on Monday, December 7 by TH Capital. Cowen & Co maintained the shares of LMAT in a report on Thursday, April 21 with “Outperform” rating. Barrington Research upgraded LeMaitre Vascular Inc (NASDAQ:LMAT) on Wednesday, October 28 to “Outperform” rating. The stock has “Buy” rating given by Roth Capital on Tuesday, May 3. Benchmark maintained it with “Buy” rating and $14 target price in Wednesday, July 29 report. The company was downgraded on Thursday, September 22 by Sidoti. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Buy” rating by Roth Capital on Monday, December 7. The stock of LeMaitre Vascular Inc (NASDAQ:LMAT) earned “Buy” rating by Stifel Nicolaus on Friday, December 4.

According to Zacks Investment Research, “LEMAITRE VASCULAR, INC. is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of twelve well-known brand name products used in arteries and veins outside of the heart and are supported by a growing, specialized and highly trained organization of vascular sales professionals. LeMaitre Vascular offers a wide range of innovative products to vascular surgeons and interventionalists for improving procedure efficacy and minimizing patient recovery time.”

Insitutional Activity: The institutional sentiment decreased to 1.24 in 2016 Q2. Its down 0.79, from 2.03 in 2016Q1. The ratio dived, as 6 funds sold all LeMaitre Vascular Inc shares owned while 31 reduced positions. 12 funds bought stakes while 34 increased positions. They now own 10.35 million shares or 1.88% more from 10.16 million shares in 2016Q1.
Timpani Mgmt Lc accumulated 0.3% or 49,402 shares. Gsa Ltd Liability Partnership last reported 172,203 shares in the company. State Street owns 291,729 shares or 0% of their US portfolio. Menta Cap Ltd Liability Corp accumulated 18,881 shares or 0.04% of the stock. Federated Invsts Pa accumulated 58,456 shares or 0% of the stock. Greenleaf Tru holds 0.01% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 14,738 shares. Monarch Partners Asset Mngmt Lc reported 18,470 shares or 0.03% of all its holdings. Eagle Glob Limited Liability holds 0.02% of its portfolio in LeMaitre Vascular Inc (NASDAQ:LMAT) for 39,563 shares. Us Bank De accumulated 0% or 405 shares. Eam Invsts Llc accumulated 0.46% or 213,177 shares. Renaissance Lc reported 99,300 shares or 0% of all its holdings. Tci Wealth owns 34 shares or 0% of their US portfolio. The California-based Schwab Charles Inv has invested 0% in LeMaitre Vascular Inc (NASDAQ:LMAT). Systematic Finance Mgmt L P last reported 78,025 shares in the company. Metropolitan Life Ins Ny holds 11,330 shares or 0% of its portfolio.

Insider Transactions: Since May 11, 2016, the stock had 0 insider purchases, and 27 selling transactions for $7.62 million net activity. The insider Roberts David B sold $135,829. $95,059 worth of LeMaitre Vascular Inc (NASDAQ:LMAT) was sold by LeMaitre George W on Friday, August 5. The insider Gebauer Peter R sold 6,310 shares worth $94,374. The insider Kamke Trent G sold 16,465 shares worth $247,307. Shares for $85,733 were sold by LeMaitre Cornelia W. The insider Jasinski Lawrence J sold 4,924 shares worth $73,821.

Another recent and important LeMaitre Vascular Inc (NASDAQ:LMAT) news was published by which published an article titled: “LeMaitre Vascular to Present at Three Investor Conferences in November” on November 08, 2016.

LMAT Company Profile

LeMaitre Vascular, Inc., incorporated on June 15, 1998, is a well-known provider of medical devices for the treatment of peripheral vascular disease. The Firm and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. The Company’s portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch. The Company’s principal product offerings are sold across the world, primarily in the United States, Europe, Asia and the Pacific Rim. The Company’s subsidiaries include LeMaitre Vascular GmbH, LeMaitre Vascular GK, Vascutech Acquisition LLC, LeMaitre Acquisition LLC, LeMaitre Vascular SAS, LeMaitre Vascular S.r.l., LeMaitre Vascular Spain SL, LeMaitre Vascular Switzerland GmbH, LeMaitre Vascular ULC, LeMaitre Vascular AS, LeMaitre Vascular Pty Ltd, and Xenotis Pty Ltd.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment